respiratory
Pulmonary fibrosis

Mycophenolate backed in scleroderma-related interstitial lung disease


Treatment of scleroderma-related interstitial lung disease with mycophenolate mofetil for two years or cyclophosphamide for one year both significantly improve lung function, according to the SLS II trial just published in the Lancet. The findings support the potential effectiveness of both approaches, and also the current preference for mycophenolate because of its better tolerability and ...

Already a member?

Enter your email to keep reading.


OR